Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-to-crypto transfers, supporting multiple stablecoins and blockchains. Meanwhile, Ethereum staking has been introduced by Interactive Brokers, boosting Ethereum's yield potential and supporting a $12,000 price target. Cardano also recorded a record 1.78 million transactions in five days, fueling optimism for its price to reach $3. Remittix offers a new crypto investment opportunity with a clear launch date and multiple products advancing toward market readiness.
The new crypto launch of Remittix's RTX token is the subject, with Pluang market data providing context. For readers following US stocks on Pluang, 38 out of 150 stocks rose while 112 fell. Notable movers include OPEN at USD 1.98 with a -6.16% change and 100% sell order activity, MRVL at USD 252.40 down 6.07%, and UPST at USD 22.41 down 5.98% but with 100% buy order activity, as of Oct 14, 2026 23:21 WIB.
BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Canary Capital has launched the Canary Staked INJ ETF (INJC) on Nasdaq, providing investors exposure to INJ, the native token of the Injective blockchain. The ETF not only tracks INJ's price but also earns staking rewards from the network's proof-of-...
The Ozempic market, valued at $30.04 billion in 2026, is projected to grow to $113.95 billion by 2032, with a CAGR of 24.89%. This growth is fueled by increasing demand for diabetes and metabolic health treatments, wider adoption of GLP-1 therapies, ...
Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...
